CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD)
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1 - 16 . (canceled)
17 . A method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by one or more pathogens other than PCVB comprising the step administering to said pig(s) an effective amount of PCVB antigen or an immunogenic composition comprising PCVB antigen.
18 . A method for improving the resistance of pigs against concomitant infections with one or more pathogens other than PCVB, comprising the step administering to said pig(s) an effective amount of PCVB antigen or an immunogenic composition comprising PCVB antigen.
19 . The method according to claim 17 or claim 18 , characterized in that the concomitant infection is caused by a viral, bacterial and/or fungal pathogen.
20 . The method according to claim 19 , characterized in that the concomitant infection is caused by viral pathogen.
21 . The method according to claim 20 , characterized in that the concomitant infection is caused by PRRS.
22 . The method according to claim 19 , characterized in that concomitant infection is caused by a bacterial pathogen.
23 . The method according to claim 19 , characterized in that the concomitant infection is caused by an enteric pathogen.
24 . The method according to claim 19 , characterized in that the concomitant infection is caused by Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Streptococcus suis.
25 . The method according to any one of claims 17 to 24 , characterized in that the pigs or the herd of pigs are/is infected with PCVB.
26 . The method according to any one of claims 17 to 25 , characterized in that the percentage of concomitant infection is reduced with regard to one or more of said infections for more than 10% as compared to a non-vaccinated control group.
27 . The method according to any one of claims 17 to 26 , characterized in that the PCVB antigen is killed PCVB, modified live PCVB or any immunogenic part thereof.
28 . The method according to any one of claims 17 to 27 , characterized in that the PCVB antigen is or comprises PCVB ORF'2.
29 . Use of PCVB antigen for the preparation of an immunogenic composition for the reduction of concomitant infections caused by one or more pathogens other than PCVB in pigs or a herd of pigs.
30 . The use according to claim 29 , characterized in that the concomitant infection is caused by a viral, bacterial and/or fungal pathogen.
31 . The use according to claim 30 , characterized in that the concomitant infection is caused by a viral pathogen.
32 . The use according to claim 31 , characterized in that the concomitant infection is caused by PRRS.
33 . The use according to claim 30 , characterized that concomitant infection is caused by a bacterial pathogen.
34 . The use according to claim 30 , characterized in that the concomitant infection is caused by Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Streptococcus suis.
35 . The use according to any one of claims 29 - 34 , characterized in that the pigs or the herd of pigs are/is infected with PCVB
36 . The use according to any one of claims 29 to 35 , characterized in that the percentage of the concomitant infection is reduced with regard to one or more of said infections for more than 10% as compared to a non-vaccinated control group.
37 . The use according to any one of claims 29 to 36 , characterized in that the PCVB antigen is killed PCVB, modified live PCVB or any immunogenic part thereof.
38 . The use according to any one of claims 29 to 37 , characterized in that the PCVB antigen is or comprises PCVB ORF'2.